HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bernadett Szabados Selected Research

Carcinoma (Carcinomatosis)

12/2023Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
3/2023First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients.
2/2022Avelumab in locally advanced or metastatic urothelial carcinoma.
1/2022Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).
12/2021Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer.
1/2021Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition.
1/2021Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
1/2020Immune checkpoint inhibition in urothelial carcinoma.
1/2020Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
1/2020Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bernadett Szabados Research Topics

Disease

17Renal Cell Carcinoma (Grawitz Tumor)
03/2024 - 01/2018
14Neoplasms (Cancer)
10/2023 - 01/2018
13Carcinoma (Carcinomatosis)
12/2023 - 01/2018
6Urinary Bladder Neoplasms (Bladder Cancer)
03/2023 - 01/2018
5Kidney Neoplasms (Kidney Cancer)
01/2024 - 08/2020
2Brain Neoplasms (Brain Tumor)
01/2024 - 03/2023
2Neoplasm Metastasis (Metastasis)
01/2023 - 01/2022
1Non-Muscle Invasive Bladder Neoplasms
12/2023
1Inflammation (Inflammations)
09/2022
1Disease Progression
01/2022
1Fatigue
01/2021
1Adrenal Insufficiency (Adrenal Gland Hypofunction)
01/2021
1Infections
08/2020
1COVID-19
08/2020
1Urogenital Neoplasms
01/2020
1Nephritis
08/2018

Drug/Important Bio-Agent (IBA)

10Immune Checkpoint InhibitorsIBA
03/2024 - 01/2018
8Biomarkers (Surrogate Marker)IBA
03/2024 - 11/2019
7atezolizumabIBA
12/2023 - 11/2019
5Cisplatin (Platino)FDA LinkGeneric
03/2023 - 01/2020
4NivolumabIBA
11/2023 - 08/2020
4IpilimumabIBA
11/2023 - 08/2020
3Tyrosine Kinase InhibitorsIBA
01/2023 - 01/2020
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2023 - 01/2020
2Hemoglobins (Hemoglobin)IBA
03/2024 - 01/2023
2PlatinumIBA
03/2023 - 01/2020
2CytokinesIBA
09/2022 - 07/2021
2Interleukin-10 (Interleukin 10)IBA
09/2022 - 07/2021
2cabozantinibIBA
01/2022 - 01/2021
1LigandsIBA
12/2023
1durvalumabIBA
10/2023
1thiaclopridIBA
10/2023
11- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA
10/2023
1Immunoconjugates (Immunoconjugate)IBA
03/2023
1enfortumab vedotinIBA
03/2023
1avelumabIBA
02/2022
1AlbuminsIBA
01/2022
1Transaminases (Aminotransferases)IBA
01/2021
1Carboplatin (JM8)FDA LinkGeneric
01/2021
1B7-H1 AntigenIBA
01/2021
1SteroidsIBA
08/2020
1Sodium Glutamate (Accent)IBA
01/2020
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2020
1Sunitinib (Sutent)FDA Link
01/2020
1Tumor Biomarkers (Tumor Markers)IBA
11/2019

Therapy/Procedure

16Therapeutics
01/2024 - 01/2018
9Immunotherapy
12/2023 - 01/2019
7Nephrectomy
10/2023 - 08/2018
6Drug Therapy (Chemotherapy)
03/2023 - 01/2018
4Cystectomy
03/2023 - 11/2019
1Transurethral Resection of Bladder
12/2023
1Aftercare (After-Treatment)
11/2019
1Contraindications
09/2019